Clinical trials lead to FDA approval of two drugs for acute myeloid leukemia
Researchers in MD Anderson’s Leukemia department played central roles in the studies of two drugs, glasdegib and venetoclax, approved in November by the Food and Drug Administration (FDA) for treatment of acute myeloid leukemia (AML) in patients not eligible for intensive chemotherapy.
Glasdegib, a hedgehog pathway inhibitor developed by Pfizer Inc., was approved for treatment following studies led by Jorge Cortes, M.D., professor...
Her discovery expanded our knowledge of cancer genetics
Shortly after arriving at MD Anderson in 1987 as a junior faculty member, Guillermina Lozano, Ph.D., attended several seminars hosted by the...
Immune helper cells appear to fuel pancreatic cancer development
Immune cells that rush to repair damage caused by inflammatory tissue are subverted to cancer-promoting allies by pancreas cells that feature...
Fidler honored for landmark findings on cancer metastasis
The American Association for Cancer Research (AACR) has selected Isaiah J. Fidler, D.V.M., Ph.D., professor of Cancer Biology, as recipient of this year’s Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research.
The award was presented to Fidler on April 15 in Chicago at the AACR’s annual meeting.
In cancer firsts, Fidler and Margaret Kripke, Ph.D., MD Anderson professor emerita of Immunology...
Removing melanoma's cloak of immune invisibility
Melanoma cells are able to evade cancer immunotherapy by using a specific protein to hide from immune system T cells out to seek and destroy...
Six MD Anderson researchers chosen for AAAS
In recognition of their contributions to basic, translational, and clinical research, six faculty members from MD Anderson Cancer Center have...
Identifying an enzyme that keeps ovarian cancer safe from immune attacks
A study of high-grade ovarian cancer has shown the enzyme protein kinase C iota (PRKCI) to be an ovarian oncogene, suggesting PRKCI inhibition...
Targeting a genetic mutation that causes many cancers
A study at MD Anderson Cancer Center has shown promise for effective treatment of therapy-resistant cancers caused by a mutation...
Is this enzyme the key to the formation of highly malignant brain cancer?
There are many moving parts when it comes to the mechanics of how otherwise healthy cells are transformed into those that cause deadly cancers...
Immunotherapy pioneer named one of TIME's most influential people
MD Anderson Chair of Immunology Jim Allison, Ph.D., whose pivotal work to attack cancer by treating the immune system instead of...